Earlier quoted context omitted.
The idea is that cancer cells have this mutant DNA clamp[0], which rallies DNA repair mechanisms in cells. The molecule targets the mutant clamp, disabling repair mechanisms for tumor cells but not healthy cells. We all should hope that it has high specificity for the mutant PCNA, and doesn't affect healthy cells... clinical trials will investigate this. [0] https://en.m.wikipedia.org/wiki/Proliferating_cell_nuclear_…
I don’t think this is targeting a mutated version of PCNA… that would assume that all cancers had the same mutation. Instead, this would target both healthy and cancerous cells. However, the idea is that the cancer cells are more susceptible to the drug. Healthy cells will be affected, but cancer cells will be affected more, and are more unstable, so losing PCNA will have more of an effect on the cancer cells. The ma…
It is targeting a mutated version.
https://www.cell.com/cell-chemical-biology/fulltext/S2451-94...